ATAI
AtaiBeckley Inc. is a clinical-stage biotechnology company developing psychedelic-based neuroplastogens for difficult-to-treat mental health conditions, with lead programs including BPL-003 (nasal spray mebufotenin for treatment-resistant depression), VLS-01 (buccal film dimethyltryptamine for treatment-resistant depression), and EMP-01 (oral R-MDMA for social anxiety disorder), alongside a drug discovery program focused on novel non-hallucinogenic 5-HT2AR agonists for treatment-resistant depression and opioid use disorder. The company's pipeline consists of wholly owned psychedelic product candidates targeting neuropsychiatric indications including depression and anxiety, positioned to address the significant unmet need in mental health treatment where approximately 65% of patients do not achieve remission after standard antidepressant trials.